Seelos Therapeutics, Inc. SEELQ · Stock Open Seelos Therapeutics, Inc. in new tab
Seelos Therapeutics, Inc. Analysis (SEELQ)
Is Seelos Therapeutics, Inc. a good investment? Seelos Therapeutics, Inc. (SEELQ) is currently trading at 0.000100 USD.
In terms of valuation, the stock trades at a P/E ratio of 0.00. This relatively low multiple may signal that Seelos Therapeutics, Inc. is undervalued compared to historical market norms.
Investor FAQ
Does Seelos Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Seelos Therapeutics, Inc.?
Seelos Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
Company Profile
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; SLS-007, a peptidic inhibitor for NACore Parkinson disease; and SLS-009, a protein targeted autophagy for Alzheimer disease. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York. On November 16, 2024, Seelos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
| Split Date | Split Ratio to 1 |
|---|---|
| June 21, 2010 | 1:15 |
| Oct. 24, 2016 | 1:10 |
| Jan. 24, 2019 | 1:30 |
| Nov. 28, 2023 | 1:30 |
| May 16, 2024 | 1:8 |
| Sept. 27, 2024 | 1:16 |
Community Discussion